Described herein are compounds, pharmaceutical compositions and methods for treating cancer, inflammation, or autoimmune disease in a subject, or for inhibiting histone methyltransferase G9a. This catalyst is immobilized on an inorganic support and contains at least one active rhenium compound containing at least one carbene group and, if desired, further functional groups. Also, the interfacing circuitry includes a synchronization section that operates at a third frequency C3, which, in one embodiment, is greater than and a whole number multiple of C2. The controller monitors a current of a power supply loop of the oscillator and a voltage of the oscillator and determines a duty cycle as a function of the monitored voltage and current. At least one of the first and second harness guides is a rotatable guide roller.